Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5 % or Framingham risk > 20 %: post hoc analyses of the JUPITER trial requested by European health authorities. - Koenig,W.; Ridker,P.M. (Eur Heart J, 2010)